Artelo Biosciences (NASDAQ:ARTL) (NASDAQ:ARTL) is a clinical-stage biotechnology company focused on developing innovative therapies that harness the endocannabinoid system and nitric oxide pathways to address a variety of neurological and ophthalmic disorders. Founded in 2017 and headquartered in Cambridge, Massachusetts, Artelo Biosciences leverages its proprietary chemistry platform to create novel small molecules that combine the therapeutic potential of cannabinoids with the vasodilatory and neuroprotective properties of nitric oxide donors.
The company’s lead product candidate, ART27.13, is a dual-action nitric oxide-releasing cannabinoid derivative aimed at treating glaucoma and other ocular conditions by reducing intraocular pressure and protecting retinal ganglion cells. Another program, ET-021, is being advanced for the management of chronic neuropathic pain and post-traumatic stress disorder, utilizing the anti-anxiety and analgesic profiles of endocannabinoid modulation. Together, these programs underscore Artelo’s strategy of combining two powerful biological pathways to generate differentiated clinical outcomes.
Artelo Biosciences operates through internal research and development teams in the United States, while collaborating with contract development and manufacturing organizations (CDMOs) both domestically and internationally for scale-up and production of clinical trial materials. The company has also engaged in strategic partnerships to explore additional indications and expand its pipeline into areas such as migraine and epilepsy. This collaborative model allows Artelo to maintain a lean organizational structure while accessing specialized expertise and global manufacturing capabilities.
Under the leadership of President and Chief Executive Officer Cory Batey, Artelo has built a multidisciplinary team of scientists, clinicians, and industry veterans committed to advancing its novel therapeutic candidates through regulatory milestones. The organization continues to engage with key opinion leaders, regulatory agencies, and patient advocacy groups to ensure rigorous clinical evaluation and alignment with unmet medical needs. With a clear focus on leveraging its dual-action platform, Artelo Biosciences aims to deliver first-in-class treatments for patients suffering from serious diseases that currently have limited therapeutic options.
